Ranosidenib

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new data from several studies of compounds discovered by HUTCHMED including savolitinib, ranosidenib, fruquintinib and surufatinib, will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting taking place on May 30 – June 3, 2025 in Chicago, USA. Results from the SACHI China Phase III study of savolitinib in combination with osimertinib in patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation-positive non-small cell lung cancer (“NSCLC”) with MET amplification after disease progression on EGFR inhibitor therapy will be presented at a late breaking oral presentation. SACHI had met the pre-defined primary endpoint of progression-free survival (PFS) in a planned interim analysis. SACHI data supports the New Drug Application (NDA) for this oral-only treatment, which has been accepted and granted priority review in China. Further data with additional analysis stratified by brain metastasis status from a high MET overexpression and/or amplification treatment subset of the SAVANNAH Phase II study of the savolitinib and osimertinib combination in NSCLC patients harboring EGFR mutation and MET amplification or overexpression after progressing on osimertinib were reported. The savolitinib and osimertinib combination demonstrated better efficacy outcomes compared to savolitinib plus placebo. The combination showed promising central nervous system (“CNS”) activity, with reduced CNS progression and fewer new CNS lesions. Results will be presented from the dose-escalation stage of the Phase I study of ranosidenib (HMPL-306), a novel, small-molecule, highly selective oral dual-inhibitor of both Isocitrate dehydrogenase (“IDH”) 1 and IDH2 enzymes, being studied in patients with locally advanced or metastatic solid tumors with IDH mutations. Results show that the compound was well tolerated, showing target inhibition and durable responses in patients. Efficacy signals were observed especially in the efficacy evaluated group of lower-grade glioma patients (N=14), with an objective response rate (“ORR”) of 7.1% and a disease control rate (“DCR”) of 100%. Results will also be presented from the sub-group analyses of the FRUSICA-1 open-label, single-arm, pivotal Phase II study to evaluate the efficacy and safety of fruquintinib plus sintilimab in previously treated advanced endometrial cancer (EMC) patients with pMMR (proficient mismatch repair) status. Efficacy findings for patients with serous carcinoma (N=27) were clinically meaningful and characterized by responses similar to those observed in full trial population (N=98), with an Independent Review Committee (“IRC”)-assessed ORR of 37.0% and a DCR of 88.9%. The analysis of whether the response was affected by prior neoadjuvant/adjuvant chemotherapy (“NACT/ACT”) showed durable and clinically meaningful responses regardless of whether the patient had received NACT/ACT. Results were comparable for patients with and without prior NACT/ACT, with an IRC-assessed ORR of 34.0% versus 31.4% and DCR of 85.1% versus 82.4%, respectively. Results from two subgroup analyses of a Phase IV study of fruquintinib involving 2,798 colorectal cancer patients in China will be presented. In the subgroup analysis evaluating the safety of fruquintinib as monotherapy and in combination therapy, fruquintinib demonstrated a manageable safety profile in both groups. Treatment-emergent adverse events (TEAE) of Grade 3 or above occurred in 23.94% in the fruquintinib monotherapy group and 26.06% in the combination therapy group with other anti-cancer treatments. The most common treatment related adverse events (TRAE) of any grade in both groups were palmar-plantar erythrodysesthesia (PPES) and hypertension. The combination therapy group exhibited a longer treatment duration, potentially indicating improved patient outcomes. In the subgroup analysis by age, the safety of fruquintinib was assessed in younger (age <50) and late-elderly (age ≥75) patients. The safety profile was comparable across both age groups, with younger patients receiving more intensive treatment. Combination therapy with fruquintinib also showed a longer duration than monotherapy in both age subgroups, which may suggest improved survival potential. Details of the presentations, including links to available abstracts, are as follows: Abstract title Presenter / Lead author Presentation details SPONSORED STUDIES Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET -amplification ( MET amp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study Shun Lu, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China LBA8505 Oral Abstract Session: Lung Cancer - Non-Small Cell Metastatic Sunday, June 1, 2025 9:48 AM CDT Efficacy and CNS results from a randomized subset of the phase 2 SAVANNAH study comparing savolitinib (savo) + osimertinib (osi) combination with savo + placebo (PBO) Benjamin Philip Levy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 8513 Rapid Oral Session: Lung Cancer - Non-Small Cell Metastatic Monday, June 2, 2025 8:06 AM CDT Phase I study of HMPL-306, an inhibitor of mutant IDH1/IDH2 (mIDH1/2), in western patients (pts) with advanced mIDH solid tumor, including glioma Jordi Rodon Ahnert, The University of Texas MD Anderson Cancer Center, Houston, TX 2013 Rapid Oral Session: Central Nervous System Tumors Saturday, May 31, 2025 3:06 PM CDT Analysis of serous carcinoma subgroup in FRUSICA-1: Fruquintinib plus sintilimab in treated advanced endometrial cancer (EMC) patients (pts) with pMMR status Xiaohua Wu, Fudan University Shanghai Cancer Center, Shanghai, China 5596 Poster Session: Gynecologic Cancer The Impact of Prior Neoadjuvant/Adjuvant Chemotherapy (NACT/ACT) on Fruquintinib Plus Sintilimab Outcomes in Advanced Endometrial Cancer (EMC) Patients with pMMR Status: A Subgroup Analysis of FRUSICA-1 Jing Wang, Hunan Cancer Hospital, Changsha, China 5611 Poster Session: Gynecologic Cancer Safety of fruquintinib in young and late-elderly Chinese patients with colorectal cancer in real-world clinical practice: Age subgroup analysis of a fruquintinib Phase IV study Yi Wang, Ningbo No.2 Hospital, Ningbo, China e15512 Publication Only: Gastrointestinal Cancer - Colorectal and Anal Safety of fruquintinib monotherapy and combination therapy in Chinese Patients with colorectal cancer in real-world clinical practice: A subgroup analysis from Phase IV study Zhiqiang Wang, Sun Yat-Sen University Cancer Center, Guangzhou, China e15515 Publication Only: Gastrointestinal Cancer - Colorectal and Anal The appropriate therapeutic sequence with angiogenesis inhibitor and chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Exploratory analysis from the Phase III FRUTIGA study Jin Li, Shanghai East Hospital, Tongji University, Shanghai, China e16011 Publication Only: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary Subgroup analysis of efficacy and safety of fruquintinib plus paclitaxel versus paclitaxel in gastroesophageal junction adenocarcinoma patients from FRUTIGA: A randomized Phase III clinical trial in second-line treatment of gastric/gastroesophageal junction Tianshu Liu, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China e16012 Publication Only: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary INVESTIGATOR-INITIATED STUDIES Fruquintinib in combination with camrelizumab and paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): a single-arm, Phase II study Yanhong Gu, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China 4042 Poster Session: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary Updated results of fruquintinib combined with PD-1 inhibitors and chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma (FDZL-FIX): a single-arm, open-label Phase II study Chenchen Wang, Fudan University Shanghai Cancer Center, Shanghai, China 4046 Poster Session: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary Open-label, single-arm, single-center Phase Ib/II clinical study of fruquintinib combined with trastuzumab and XELOX in the first-line treatment of advanced HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma Huifang Lv, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China TPS4203 Poster Session: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary A multi-cohort real-world study of treatment for metastatic colorectal cancer (mCRC): Overall efficacy analysis and subgroup analysis of previous bevacizumab use or not Wangxia Lv, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China e15530 Publication Only: Gastrointestinal Cancer - Colorectal and Anal Real-world Observational Study of Fruquintinib in Combination with Irinotecan and Capecitabine as Second-line Treatment in Patients with Advanced Colorectal Cancer Ling Xu, the First Hospital of China Medical University, Shenyang, China e15539 Publication Only: Gastrointestinal Cancer - Colorectal and Anal Preliminary results of fruquintinib in combination with FOLFIRI as second-line treatment for RAS-mutant metastatic colorectal cancer: a prospective single-center Phase II study Ru Jia, Fifth Medical Center, Chinese PLA General Hospital, Beijing, China e15541 Publication Only: Gastrointestinal Cancer - Colorectal and Anal Evaluating the efficacy of fruquintinib versus regorafenib and trifluridine/tipiracil in treating advanced metastatic colorectal cancer: A match-adjusted indirect comparison Shukui Qin, Gastrointestinal Cancer Center of Nanjing Tianyinshan Hospital, China Pharmaceutical University, Nanjing, China e15550 Publication Only: Gastrointestinal Cancer - Colorectal and Anal Fruquintinib plus sintilimab and SOX as conversion therapy for initially unresectable gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated response and surgical results from a single-arm, Phase II clinical trial Fei Ma, Henan Cancer Hospital, Zhengzhou, China e16016 Publication Only: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary A Phase II study to evaluate the efficacy and safety of fruquintinib combined with envafolimab in patients with advanced or unresectable locally advanced osteosarcoma and soft tissue sarcoma Chenliang Zhou, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China e23506 Publication Only: Sarcoma Efficacy and safety of surufatinib (Sur) plus paclitaxel (Pac) as second line (2L) treatment for advanced gastric cancer (aGC): Final results from a Phase II trial Xiuying Xiao, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China 4028 Poster Session: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary Efficacy and safety of surufatinib (S) plus KN046 (K) and chemotherapy in first line (1L) advanced pancreatic cancer (PC): a single-arm, Phase Ib/II trial Wenquan Wang, Zhongshan Hospital, Fudan University, Shanghai, China 4157 Poster Session: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary First-Line Treatment with Surufatinib, Camrelizumab, Nab-paclitaxel, and S-1 in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC): A Phase Ib/II Randomized Study Ru Jia/ Guanghai Dai, the Fifth Medical Center of the PLA General Hospital, Beijing, China 4161 Poster Session: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary A prospective, single-arm, Phase II trial exploring the use of pamiparib combined with surufatinib as neoadiuvant therapy for advanced, unresectable ovarian cancer (PASSION) Bairong Xia, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China 5589 Poster Session: Gynecologic Cancer The efficacy and safety of Surufatinib monotherapy as a third-line treatment for advanced hepatocellular carcinoma: A single-arm, open-label, multi-center Phase II study Fuxiang Zhou, Zhongnan Hospital of Wuhan University, Wuhan, China e16209 Publication Only: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary Surufatinib combined with gemcitabine and cisplatin and immune checkpoint inhibitor (ICI) for unresectable locally advanced or metastatic intrahepatic cholangiocarcinoma Jingtao Zhang/ Xuetao Shi, Cancer Hospital of Shandong First Medical University, Jinan, China e16222 Publication Only: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary Updated results from a multicenter, single-arm Phase II study of surufatinib plus sintilimab and lBl310 in patients with high-grade advanced neuroendocrine neoplasm (HG-NEN) Ming Lu/ Lin Shen, Peking University Cancer Hospital, Beijing, China e16342 Publication Only: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary A prospective, single-arm, Phase II study of surufatinib in combination with gemcitabine and nab-paclitaxel for the neoadjuvant treatment of resectable and borderline resectable pancreatic cancer Song Gao/ Jihui Hao, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China e16442 Publication Only: Gastrointestinal Cancer - Gastroesophageal, Pancreatic, and Hepatobiliary About HUTCHMED HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including but not limited to its expectations regarding the therapeutic potential of savolitinib, ranosidenib, fruquintinib and surufatinib, the further clinical development for savolitinib, ranosidenib, fruquintinib and surufatinib, its expectations as to whether any studies on savolitinib, ranosidenib, fruquintinib and surufatinib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of savolitinib, ranosidenib, fruquintinib and surufatinib, including as combination therapies, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential markets of savolitinib, ranosidenib, fruquintinib and surufatinib for a targeted indication, and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. Medical Information This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. CONTACTS Investor Enquiries +852 2121 8200 / ir@hutch-med.com Media Enquiries FTI Consulting – +44 20 3727 1030 / HUTCHMED@fticonsulting.com Ben Atwell / Alex Shaw +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) Brunswick – Zhou Yi +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com Panmure Liberum Nominated Advisor and Joint Broker Atholl Tweedie / Freddy Crossley / Rupert Dearden +44 20 7886 2500 HSBC Joint Broker Simon Alexander / Alina Vaskina / Arnav Kapoor +44 20 7991 8888 Cavendish Joint Broker Geoff Nash / Nigel Birks +44 20 7220 0500 Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

撰文 | 殷丹妮   //   • vorasidenib同时靶向IDH1、IDH2两个突变位点，通过双重抑制来解决胶质瘤的耐药； • 规避传统治疗10%概率出现的超突变进展至高级别胶质瘤； • 目前已启动一项一线治疗研究、两项联合用药研究； • 施维雅目标是在2030年实现肿瘤业务营收不低于30亿欧元。 首个针对IDH突变低级别胶质瘤的小分子靶向药物出现了。 2024年8月，FDA批准Voranigo®（vorasidenib）上市。这款可穿透血脑屏障、同时针对IDH1和IDH2突变的双重抑制剂，给IDH突变型低级别胶质瘤患者带来治疗新希望。 vorasidenib的获批是施维雅围绕IDH布局肿瘤业务的重要节点之一。进一步的规划，除了在IDH中拓展适应症的一线治疗、或是联合PD-1治疗高级别肿瘤，施维雅还借力AI技术、及外部合作持续开发创新靶点药物。结合已上市肿瘤产品的销售业绩，施维雅在肿瘤领域形成了早期创新发现、临床拓展以及持续商业化的完整布局。 面对中国市场，8月31日vorasidenib桥接研究在北京正式启动。该研究由江涛院士牵头，首都医科大学附属北京天坛医院担任组长单位,针对患有IDH1或IDH2突变的残留或复发2级胶质瘤的亚洲受试者进行3期、多中心、随机、双盲、安慰剂对照研究。 这项研究的启动，标志着中国在胶质瘤治疗领域的新进展，对于提升国内临床研究水平、推动新药研发具有重要意义。 全球首个IDH1/2抑制剂 vorasidenib会给IDH突变型低级别胶质瘤整体的未来治疗策略带来革命性变化，复旦大学附属华山医院吴劲松教授这样认为。 为什么如此评价，首先看疾病的未满足需求。脑胶质瘤是最常见的颅内恶性肿瘤，病死率极高，且缺乏有效的药物治疗。异柠檬酸脱氢酶（IDH）突变是脑胶质瘤中常见突变类型，通常发生在疾病早期。vorasidenib针对的就是早期、低级别胶质瘤中的IDH突变型患者，低级别脑胶质瘤约占脑胶质瘤的30%，其中近70%的低级别脑胶质瘤发生IDH突变，患者群体大。 该类患者目前的标准治疗是手术后采用放疗联合化疗方式。放化疗的副作用除了已知的急慢性相关毒性外，有文献报道，IDH突变低级别胶质瘤如果采用替莫唑胺化疗，可能诱发超突变进展至高级别胶质瘤，虽然概率只有10%。 而vorasidenib治疗能规避这10%的概率，且不会引发放化疗副作用。不仅如此，vorasidenib在IDH突变胶质瘤中还有两方面的治疗优势。 其一vorasidenib是全球首款同时针对IDH1、IDH2两个突变位点的抑制剂，几乎覆盖了所有IDH突变型低级别胶质瘤。且有数据表明，单一靶向IDH1或IDH2突变，两者突变易互相转化导致耐药，双重的抑制剂能解决耐药问题。 其二vorasidenib的分子设计使其可透过血脑屏障，其血脑屏障渗透率高于另一款IDH1抑制剂ivosidenib，增加了中枢神经系统的血药浓度，以及提高药物治疗有效性。 突破一线可能性 施维雅首席商务官Arjun H. Prasad认为，vorasidenib前所未有地改善了脑胶质瘤的疾病无进展生存期。从其3期关键研究INDIGO的结果看确实如此。 这项全球、随机、双盲、安慰剂对照研究，于2020年1月入组首例患者，对象为仅接受手术治疗且出现残留或复发的IDH1/2突变2级胶质瘤患者，共招募331例受试者。研究在2023年3月的第二阶段期中分析时成功达到了主要疗效终点及关键次要终点，共耗时约3年时间。 来源|medscape 具体数据看，vorasidenib的主要终点中位无进展生存期（PFS）达到27.7个月，而安慰剂组为11.1个月。关键次要终点至下一次干预时间（TTNI）具备统计学显著性，vorasidenib组的中位TTNI尚未达到，而安慰剂组为17.8个月。其他数据，vorasidenib组每6个月的肿瘤体积平均减少2.5%，而安慰剂组每6个月的肿瘤体积平均增加13.9%。 同时，施维雅正在进一步挖掘vorasidenib的潜力。 目前已启动一线治疗4级星形细胞瘤的2期临床、联合PD-1抑制剂pembrolizumab的1期临床、以及联合替莫唑胺治疗IDH1或IDH2突变脑胶质瘤的1b/2期临床研究。对vorasidenib的临床布局，可以看出施维雅对产品朝一线拓展以及联合用药方面的规划。 INDIGO研究针对的是低级别胶质瘤患者，而高级别（III/IV级）脑胶质瘤的治疗，才是真正的行业痛点，预后差的大多数是高级别患者。往一线的高级别患者拓展，也是vorasidenib自证疗效实力的方式之一。 与PD-1的联合治疗，吴劲松在解读时表示，IDH突变会造成肿瘤微环境的免疫抑制，免疫检查点抑制剂难以发挥疗效，而IDH抑制剂可以阻断这些效应，使微环境从“冷”变“热”，对肿瘤发挥协同免疫抑制作用。 同时，与pembrolizumab联合的1期研究已有部分结果公布，在7例复发或进展增强型IDH1突变的2/3级星形细胞瘤患者中，使用探索剂量是安全且可耐受。 从临床结果看，vorasidenib已在脑胶质瘤中达到了预期疗效结果，再结合疾病需求、分子设计，即印证了上述吴劲松的观点，vorasidenib将革新IDH突变型低级别胶质瘤的治疗策略，给该类患者带来治疗的新希望。 此外，针对vorasidenib的中国市场，施维雅也已开始布局。施维雅中国总经理Manuel RUIZ表示，vorasidenib在美国批准是一个重要里程碑，施维雅正在尽快将这一创新产品带入中国。 2024年6月，vorasidenib的3期临床试验方案在中国获得批准。同月，施维雅与艾德生物达成战略合作伙伴关系，艾德生物将开发vorasidenib的伴随诊断试剂，助力其在中国大陆的注册和商业化。 “同时面对中国脑胶质瘤患者对vorasidenib的迫切治疗需求，施维雅正积极与海南博鳌乐城、北京天竺、大湾区等具备优先准入的试点区域、或地方监管机构合作，尽可能在正式批准前，提早进入部分地区惠及有迫切需求的患者。” Manuel RUIZ说。 领跑全球IDH研发 在如今靶点内卷的时代，IDH抑制剂领域犹如一片蓝海。在这片蓝海赛道中，施维雅可谓遥遥领先，不仅拥有IDH1/2抑制剂Voranigo（vorasidenib），还有已上市的IDH1抑制剂Tibsovo（ivosidenib）、IDH2抑制剂Idhifa（enasidenib）。 疾病范畴覆盖胆管癌、脑胶质瘤等实体瘤，以及急性髓系白血病（AML）、骨髓增生异常综合征（MDS）等血液肿瘤，已获批6个适应症。 相比下，IDH赛道中其他产品，除了已上市的Rezlidhia（olutasidenib），仅有和黄医药的HMPL-306和正大天晴的TQB-3454处在3期临床阶段。可见未来施维雅在IDH赛道中，不论是双突变还是单突变，还将领跑相当长一段路程。 面对IDH这一蓝海，施维雅还在乘胜追击。 对于ivosidenib的临床拓展，施维雅在IDH1突变的胆管癌一线及二线、软骨肉瘤一线及二线、急性髓系白血病（AML）一线、以及骨髓增生异常综合征（MDS）的一线治疗中，均有临床试验正在进行中。 未来，施维雅将如何持续押注肿瘤，值得期待。目前，施维雅管线中的其他肿瘤在研产品覆盖到MET、TIM3、CD73、PD-L1/4-1BB、NKG2A、MAT2A等多个靶点，适应症拓展至非小细胞肺癌等实体瘤。 来源|施维雅官网 施维雅进军肿瘤领域是自2018年收购Shire肿瘤业务开始，后又通过收购Agios Pharmaceuticals、丹麦Symphogen公司持续公司在肿瘤领域的管线。其中vorasidenib是2020年收购Agios Pharmaceuticals所获得，也是施维雅专注肿瘤业务的标志性事件之一。 而后，施维雅不断通过外部合作模式拓展其早期临床管线，包括与GNS合作开发多发性骨髓瘤药物，与Oncodesign合作探索胰腺癌治疗新靶点、与Gustave Roussy签署肿瘤学合作框架协议。此外在MNC竞相拥抱AI的当下，施维雅也不例外，分别与人工智能公司Aqemia、Owkin合作开发创新靶点的小分子药物，并建立了自己的AI平台Patrimony，并利用平台开发出几个创新靶点药物。 已上市的肿瘤产品已给施维雅带来持续的销售业绩。2022~2023财报显示，公司的肿瘤药物收入突破10亿欧元，同比上涨26.7%。肿瘤收入占整个公司收入比例上升至20%，上一年的收入占比为17.4%。 施维雅曾在2022年发布2030集团发展目标，在2030年实现肿瘤业务营收不低于30亿欧元。相信随着vorasidenib的获批，以及围绕IDH展开的肿瘤业务，同时并借力AI技术不断开发创新肿瘤产品，施维雅在肿瘤领域的持续规划将助其实现目标。 编辑 | 姚嘉 yao.jia@PharmaDJ.com  总第2195期 访问研发客网站，深度报道和每日新闻抢鲜看 www.PharmaDJ.com